<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103735</url>
  </required_header>
  <id_info>
    <org_study_id>CRANIO-UDINE</org_study_id>
    <nct_id>NCT05103735</nct_id>
  </id_info>
  <brief_title>Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity</brief_title>
  <official_title>Propofol-remifentanil Versus Dexmedetomidine in Awake Craniotomy: an Intraoperative Neurophysiological Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria-Universitaria Integrata di Udine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Sanitaria-Universitaria Integrata di Udine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Awake craniotomy require a cooperative patient during resection neurosurgery phase.&#xD;
      Anesthesiologist should guarantee analgesia, sedation, nausea and vomiting prevention, while&#xD;
      maintaining normal vital parameters.&#xD;
&#xD;
      Neurosurgeon could be help by Intraoperative electrocorticography to maximise lesion&#xD;
      resection and avoiding neurologic sequelae. Propofol and remifentanyl have been largely used.&#xD;
      Dexmedetomidine represents an alternative. However little is known about the role of&#xD;
      dexmedetomidine on Intraoperative electrocorticography.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Actual">October 11, 2021</completion_date>
  <primary_completion_date type="Actual">October 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SEIZURE ACTIVITY</measure>
    <time_frame>DURING TUMOR RESECTION PHASE OF THE AWAKE CRANIOTOMY</time_frame>
    <description>INCIDENCE OF ELECTRO-CLINICAL SEIZURE ACTIVITY IN THE TWO GROUPS DURING RESECTIVE PHASE OF AWAKE CRANIOTOMY EVALUATED WITH ELECTROCORTICOGRAPHY.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Craniotomy</condition>
  <condition>Seizures</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Propofol</condition>
  <condition>Remifentanil</condition>
  <condition>Cerebral Tumor</condition>
  <condition>Neurophysiology</condition>
  <arm_group>
    <arm_group_label>PROPOFOL-REMIFENTANYL</arm_group_label>
    <description>Awake craniotomy under propofol-remifentanil sedation. Propofol and remifentanyl was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.&#xD;
Propofol dosage: 0.2-2 mk/kg/h Remifentanyl dosage: 0.01-0.1 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEXMEDETOMIDINE</arm_group_label>
    <description>Awake craniotomy under dexmedetomidine sedation. Dexmedetomidine was administered through continuous intravenous infusion, starting 30 minutes prior to surgery. The end of the infusion was at the end of the surgical procedure.&#xD;
Dexmedetomidine dosage: 0.2-1 mcg/kg/h In this group, remifentanyl administration was allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>awake neurosurgery under propofol-remifentanil sedation</description>
    <arm_group_label>PROPOFOL-REMIFENTANYL</arm_group_label>
    <other_name>Remifentanil</other_name>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ALL PATIENTS UNDERGOING AWAKE CRANIOTOMY FOR TUMOR RESECTION SURGERY&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PATIENTS UNDERGOING AWAKE CRANIOTOMY FOR TUMOR RESECTION (EXCLUDED E.G. SURGERY OF&#xD;
             EPILEPSIA)&#xD;
&#xD;
          -  INTRAOPERATIVE MONITORING (IOM) WITH ELECTROCORTICOGRAPHY&#xD;
&#xD;
          -  AWAKE-AWAKE-AWAKE TECHNIQUE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AGE &lt;18 YEARS OLD&#xD;
&#xD;
          -  NON AWAKE-AWAKE-AWAKE TECHNIQUE&#xD;
&#xD;
          -  ABSENCE OF IOM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cristian Deana</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Sanitaria-Universitaria Integrata di Udine</investigator_affiliation>
    <investigator_full_name>Cristian Deana</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

